PMID- 19121337
OWN - NLM
STAT- MEDLINE
DCOM- 20091216
LR  - 20090317
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 122
IP  - 2
DP  - 2009 Feb 21
TI  - Dendritic cells from bench to bedside and back.
PG  - 128-30
LID - 10.1016/j.imlet.2008.11.017 [doi]
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells of the immune 
      system. They serve as the sentinels that capture antigens in the periphery, 
      process them into peptides and present these to lymphocytes in lymph nodes. DCs 
      play a key role in regulating immunity. Several DC-subsets exist, including 
      myeloid-DCs (MDCs), plasmacytoid-DCs (PDCs) and Langerhans cells (LC). DCs not 
      only instruct T- and B-lymphocytes, but also activate Natural Killer cells and 
      produce interferons, thus linking the innate and adaptive immune system. 
      Inflammatory-mediators and especially the Toll like receptor (TLR) family of 
      proteins have been shown to play a pivotal role in inducing the immune activation 
      program in DCs. TLRs recognize pathogen-associated-molecular-patterns (PAMPS) 
      like LPS or flagellin and signal to alert immune cells in general, and DC in 
      particular. DC activation, also referred to as DC maturation, thus results in 
      immunity. In contrast, resting DC or DC receiving immune-inhibitory signals, like 
      IL-10 and/or corticosteroids, induce immune tolerance via T cell deletion and 
      induction of suppressive T cells, now termed regulatory T cells. Several mouse 
      models have demonstrated that the immunological outcome is depending on the DC 
      activation state; mature immune-activating DC protect mice from a tumor or 
      pathogen while tolerogenic DC induces tolerance against transplanted tissues. 
      Hence, DC acts at the interface of immunity and peripheral tolerance.
FAU - Adema, G J
AU  - Adema GJ
AD  - Department of Tumorimmunology, Nijmegen Centre for Molecular Life Sciences, 
      Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 
      g.adema@ncmls.ru.nl
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20081231
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antigen Presentation/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Differentiation
MH  - Cell Movement
MH  - Cytokines/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - *Immune Tolerance
MH  - Immunotherapy, Adoptive
MH  - Lymphocyte Activation
MH  - Mice
MH  - Neoplasms/*immunology/prevention & control
MH  - Toll-Like Receptors/immunology
RF  - 15
EDAT- 2009/01/06 09:00
MHDA- 2009/12/17 06:00
CRDT- 2009/01/06 09:00
PHST- 2009/01/06 09:00 [entrez]
PHST- 2009/01/06 09:00 [pubmed]
PHST- 2009/12/17 06:00 [medline]
AID - S0165-2478(08)00264-2 [pii]
AID - 10.1016/j.imlet.2008.11.017 [doi]
PST - ppublish
SO  - Immunol Lett. 2009 Feb 21;122(2):128-30. doi: 10.1016/j.imlet.2008.11.017. Epub 
      2008 Dec 31.